Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

JNCCN Spotlights

Crizotinib (Xalkori)

News

Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC

Videos

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

News

Biomarker May Predict Susceptibility to Radiation Pneumonitis in Patients With Lung Cancer

News

Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer

News

Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC

Medical Literature

Osimertinib in Treatment of EGFR-Mutated NSCLC: From the ADAURA Trial

Benjamin Besse, MD, PhD, on Clinical Tips for Prescribing Atezolizumab as Neoadjuvant Therapy for Resectable NSCLC

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

Pembrolizumab (Keytruda) in NSCLC

Nivolumab (Opdivo) in NSCLC

Afatinib (Gilotrif)

View More

More

News

Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?

Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer

Targeting KRAS Mutations in Advanced NSCLC: Early Trial Results

Capmatinib in MET-Dysregulated Advanced NSCLC: GEOMETRY Mono-1

SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma

ESMO Asia 2020: Adding PD-L1 Inhibitor to Platinum-Based Chemotherapy for NSCLC

Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC

Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC

View More

Advertisement

Published

Medical Literature

Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer

Heat Shock Protein 90 Inhibitor in Lung Cancer: GALAXY Clinical Trials

Multikinase Inhibitors in RET-Rearranged NSCLC

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

View More

Ongoing

CE Activities

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Novel and Emerging Therapeutic Strategies in the Management of Non–Small Cell Lung Cancer

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Consensus or Controversy? Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.